BAVENCIO Informational Program

Now Approved: BAVENCIO® (avelumab) in Combination With INLYTA® (axitinib) For the first-line treatment of patients with advanced renal cell carcinoma (RCC)

An Informational Program
Featuring
SANJAY SHARMA MD

Please RSVP to your Pfizer Representative
Donna Corsell: (408) 691-0736, donna.corsell@pfizer.com
Kindly provide your full name, degree, specialty, address including state, and email address when registering so that you can be confirmed. Please also provide the Meeting ID#INT-0050490 when you RSVP